These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 226702)

  • 21. Auranofin.
    Davis P
    Clin Rheum Dis; 1984 Aug; 10(2):369-83. PubMed ID: 6239742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of a new antirheumatic drug, triethylphosphine gold (auranofin), on in vitro lymphocyte and monocyte cytotoxicity.
    Russell AS; Davis P; Miller C
    J Rheumatol; 1982; 9(1):30-5. PubMed ID: 6806471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of action of auranofin: effects on humoral immune response.
    Walz DT; Dimartino MJ; Griswold DE
    J Rheumatol Suppl; 1982; 8():32-6. PubMed ID: 6813489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Auranofin treatment for adult rheumatoid arthritis. Comparison of 2 mg and 6 mg daily dose.
    Bernhard GC
    J Rheumatol Suppl; 1982; 8():149-53. PubMed ID: 6813477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Esters of phosphonopropionic and phosphonoacetic acids: effect on synthesis of Epstein-Barr virus (EBV) antigens and on transformation of cord blood lymphocytes by EBV.
    Margalith M; Manor D; Agranat I; Bentor Y; Gelfand T; Goldblum N
    Cancer Biochem Biophys; 1980; 4(3):137-43. PubMed ID: 6254633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Auranofin and sodium aurothiomalate in the treatment of rheumatoid arthritis. A double-blind, comparative multicenter study.
    Schattenkirchner M; Kaik B; Muller-Fassbender H; Rau R; Zeidler H
    J Rheumatol Suppl; 1982; 8():184-9. PubMed ID: 6813483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The in vitro effect of gold complexes on bone resorption.
    Katz JM; Gray DH
    J Orthop Res; 1986; 4(2):188-93. PubMed ID: 3086527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Auranofin. Mechanism of action, pharmacokinetics and clinical use. Comparison with injectable gold salts].
    Chamouard JM; Clerc D; Bisson M; Medicis P; Massias P
    Rev Rhum Mal Osteoartic; 1985 Apr; 52(4):277-82. PubMed ID: 3923604
    [No Abstract]   [Full Text] [Related]  

  • 29. Studies of the intestinal metabolism of oral gold.
    Weisman MH; Hardison WG; Walz DT
    J Rheumatol; 1980; 7(5):633-8. PubMed ID: 6777493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of gold compounds on leukotriene B4, leukotriene C4 and prostaglandin E2 production by polymorphonuclear leukocytes.
    Parente JE; Wong K; Davis P; Burka JF; Percy JS
    J Rheumatol; 1986 Feb; 13(1):47-51. PubMed ID: 3009806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of auranofin dose regimen change upon cell-associated gold in rheumatoid arthritic patients.
    Walz DT; Griswold DE; DiMartino MJ; Bumbier EE
    J Rheumatol; 1981; 8(5):829-32. PubMed ID: 6796684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparative study of auranofin, gold sodium thiomalate, and D-penicillamine in rheumatoid arthritis: a progress report.
    Barraclough D; Brook A; Brooks P; Boyden K; Thomas D; Tymms K
    J Rheumatol Suppl; 1982; 8():197-200. PubMed ID: 6813485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening trial with the coordinated gold compound auranofin using mouse lymphocyte leukemia P388.
    Simon TM; Kunishima DH; Vibert GJ; Lorber A
    Cancer Res; 1981 Jan; 41(1):94-7. PubMed ID: 6778607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of auranofin in animals.
    Intoccia AP; Flanagan TL; Walz DT; Gutzait L; Swagzdis JE; Flagiello J; Hwang BY; Dewey RH; Noguchi H
    J Rheumatol Suppl; 1982; 8():90-8. PubMed ID: 6813497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of auranofin and sodium aurothiomalate on peripheral blood monocytes.
    Scheinberg MA; Santos LM; Finkelstein AE
    J Rheumatol; 1982; 9(3):366-9. PubMed ID: 6288942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An analysis of worldwide safety experience with auranofin.
    Heuer MA; Pietrusko RG; Morris RW; Scheffler BJ
    J Rheumatol; 1985 Aug; 12(4):695-9. PubMed ID: 3932651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of the molecular pharmacology of gold and platinum complexes.
    Crooke ST
    J Rheumatol Suppl; 1982; 8():61-70. PubMed ID: 6813493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Suppressed IL-2 production and response in AA rats: role of suppressor cells and the effect of auranofin treatment.
    Lee JC; Rebar L; Demuth S; Hanna N
    J Rheumatol; 1985 Oct; 12(5):885-91. PubMed ID: 2935633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One-year comparative study of gold sodium thiomalate and auranofin in the treatment of rheumatoid arthritis.
    Davis P; Menard H; Thompson J; Harth M; Beaudet F
    J Rheumatol; 1985 Feb; 12(1):60-7. PubMed ID: 3920393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of eosinophilia during gold therapy for rheumatoid arthritis.
    Edelman J; Davis P; Owen ET
    J Rheumatol; 1983 Feb; 10(1):121-3. PubMed ID: 6405032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.